IRadimed Q1 Revenue Rises 13% to $22M, Launches Next-Gen 3870 Pump
IRadimed posted Q1 revenue of $22.0 million, up 13% year-over-year, GAAP EPS of $0.45, non-GAAP EPS of $0.49 and net income of $5.8 million. It launched the next-generation 3870 MRI-compatible IV pump, set Q2 revenue guidance at $20–21 million and non-GAAP EPS at $0.44–0.48, and declared a $0.20 dividend.
1. Q1 Financial Performance
IRadimed reported first-quarter revenue of $22.0 million, marking a 13% increase over Q1 2025. The company delivered GAAP diluted EPS of $0.45 and non-GAAP EPS of $0.49, generating net income of $5.8 million on disciplined expense management.
2. Next-Generation 3870 Pump Launch
During the quarter, IRadimed commercially launched its next-generation 3870 MRI-compatible IV infusion pump system. Early order activity exceeded prior-generation levels, with significant shipments expected to commence in the second quarter.
3. Guidance Outlook
For Q2, management forecasted revenue of $20.0–$21.0 million and non-GAAP EPS of $0.44–$0.48. Full-year guidance was reaffirmed at $91.0–$96.0 million in revenue and non-GAAP EPS of $2.06–$2.21.
4. Dividend Declaration
The board declared a regular quarterly cash dividend of $0.20 per share, payable May 29 to shareholders of record as of May 15, reflecting sustained free cash flow generation.